Companies Dominating the Allergic Immunotherapy Landscape
- ALK
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Stallergenes Greer
- Mylan N.V.
- HAL Allergy B.V.
- LETIPharma
- AstraZeneca
Browse Key Market Insights with Data Illustration:
In the News
- September 2023 - As a top provider of allergen immunotherapy (AIT), Stallergenes Greer has secured agreements with Nestlé on a global scale to use the oral immunotherapy drug Palforzia® to treat peanut allergy.Upon signing, the deal was finalized.
- June 2023 – ALK recently released the preliminary findings from a Phase 3 pediatric clinical trial evaluating a sublingual allergy immunotherapy pill for the treatment of allergic rhinitis brought on by house dust mites (HDM). The HDM tablet is sold under the names MITICURETM in Japan, ODACTRA® in the USA, and ACARIZAX® in Europe and other international markets.